Ali Zarrin

Dr. Ali Zarrin is Chief Scientific Officer at TRexBio, directing scientific strategy and all stages of drug discovery from target identification to early clinical translation. He brings 18 years of experience in translational immunology, advancing therapies across cancer, autoimmune, and inflammatory diseases. Previously, he held senior R&D roles at Genentech, leading multiple programs and disease-area research strategies. Dr. Zarrin is an inventor on six patents and author of over 47 publications in top journals including Nature, Science, and PNAS. He earned his BS from the University of Minnesota, PhD in Immunology from the University of Toronto, and completed postdoctoral training at Harvard/HHMI.